Cargando…

The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience

Pandemic restrictions have led to changes in therapy plans and disrupted rehabilitation services for people with multiple sclerosis. CogEx is an international, multicentre MS dual-intervention (cognitive rehabilitation, aerobic exercise) randomized, controlled rehabilitation trial confined to people...

Descripción completa

Detalles Bibliográficos
Autores principales: Feinstein, Anthony, Amato, Maria Pia, Brichetto, Giampaolo, Chataway, Jeremy, Chiaravalloti, Nancy D., Cutter, Gary, Dalgas, Ulrik, DeLuca, John, Farrell, Rachel, Feys, Peter, Filippi, Massimo, Freeman, Jennifer, Inglese, Matilde, Meza, Cecilia, Motl, Rob, Rocca, Maria Assunta, Sandroff, Brian M., Salter, Amber
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570234/
https://www.ncbi.nlm.nih.gov/pubmed/34741240
http://dx.doi.org/10.1007/s00415-021-10881-3
_version_ 1784594801059954688
author Feinstein, Anthony
Amato, Maria Pia
Brichetto, Giampaolo
Chataway, Jeremy
Chiaravalloti, Nancy D.
Cutter, Gary
Dalgas, Ulrik
DeLuca, John
Farrell, Rachel
Feys, Peter
Filippi, Massimo
Freeman, Jennifer
Inglese, Matilde
Meza, Cecilia
Motl, Rob
Rocca, Maria Assunta
Sandroff, Brian M.
Salter, Amber
author_facet Feinstein, Anthony
Amato, Maria Pia
Brichetto, Giampaolo
Chataway, Jeremy
Chiaravalloti, Nancy D.
Cutter, Gary
Dalgas, Ulrik
DeLuca, John
Farrell, Rachel
Feys, Peter
Filippi, Massimo
Freeman, Jennifer
Inglese, Matilde
Meza, Cecilia
Motl, Rob
Rocca, Maria Assunta
Sandroff, Brian M.
Salter, Amber
author_sort Feinstein, Anthony
collection PubMed
description Pandemic restrictions have led to changes in therapy plans and disrupted rehabilitation services for people with multiple sclerosis. CogEx is an international, multicentre MS dual-intervention (cognitive rehabilitation, aerobic exercise) randomized, controlled rehabilitation trial confined to people with progressive disease. The primary outcome is cognition (processing speed).There are 11 treatment sites in six countries with participants required to make 27 site visits over 12 weeks. Collectively, the large, in-person demands of the trial, and the varying international policies for the containment of COVID-19, might disproportionately impact the administration of CogEx. During the first lockdown, all centres closed on average for 82.9 (SD = 24.3) days. One site was required to lockdown on two further occasions. One site remained closed for 16 months. Ten staff (19.2%) were required to quarantine and eight staff (15.4%) tested positive for COVID. 10 of 264 (3.8%) participants acquired COVID-19. All survived. The mean duration of enrollment delay has been [236.7 (SD = 214.5) days]. Restarting participants whose interventions were interrupted by the pandemic meant recalculating the intervention prescriptions for these individuals. While the impact of the pandemic on CogEx has been considerable, all study sites are again open. Participants and staff have shown considerable flexibility and resilience in keeping a complex, international endeavour running. The future in general remains uncertain in the midst of a pandemic, but there is cautious optimism the study will be completed with sufficient sample size to robustly evaluate our hypothesis and provide meaningful results to the MS community on the impact of these interventions on people with progressive MS. Trial registration: The trial was registered on September 20th 2018 at www.clinicaltrials.gov having identifier NCT03679468. Registration was performed before recruitment was initiated.
format Online
Article
Text
id pubmed-8570234
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85702342021-11-05 The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience Feinstein, Anthony Amato, Maria Pia Brichetto, Giampaolo Chataway, Jeremy Chiaravalloti, Nancy D. Cutter, Gary Dalgas, Ulrik DeLuca, John Farrell, Rachel Feys, Peter Filippi, Massimo Freeman, Jennifer Inglese, Matilde Meza, Cecilia Motl, Rob Rocca, Maria Assunta Sandroff, Brian M. Salter, Amber J Neurol Original Communication Pandemic restrictions have led to changes in therapy plans and disrupted rehabilitation services for people with multiple sclerosis. CogEx is an international, multicentre MS dual-intervention (cognitive rehabilitation, aerobic exercise) randomized, controlled rehabilitation trial confined to people with progressive disease. The primary outcome is cognition (processing speed).There are 11 treatment sites in six countries with participants required to make 27 site visits over 12 weeks. Collectively, the large, in-person demands of the trial, and the varying international policies for the containment of COVID-19, might disproportionately impact the administration of CogEx. During the first lockdown, all centres closed on average for 82.9 (SD = 24.3) days. One site was required to lockdown on two further occasions. One site remained closed for 16 months. Ten staff (19.2%) were required to quarantine and eight staff (15.4%) tested positive for COVID. 10 of 264 (3.8%) participants acquired COVID-19. All survived. The mean duration of enrollment delay has been [236.7 (SD = 214.5) days]. Restarting participants whose interventions were interrupted by the pandemic meant recalculating the intervention prescriptions for these individuals. While the impact of the pandemic on CogEx has been considerable, all study sites are again open. Participants and staff have shown considerable flexibility and resilience in keeping a complex, international endeavour running. The future in general remains uncertain in the midst of a pandemic, but there is cautious optimism the study will be completed with sufficient sample size to robustly evaluate our hypothesis and provide meaningful results to the MS community on the impact of these interventions on people with progressive MS. Trial registration: The trial was registered on September 20th 2018 at www.clinicaltrials.gov having identifier NCT03679468. Registration was performed before recruitment was initiated. Springer Berlin Heidelberg 2021-11-05 2022 /pmc/articles/PMC8570234/ /pubmed/34741240 http://dx.doi.org/10.1007/s00415-021-10881-3 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Communication
Feinstein, Anthony
Amato, Maria Pia
Brichetto, Giampaolo
Chataway, Jeremy
Chiaravalloti, Nancy D.
Cutter, Gary
Dalgas, Ulrik
DeLuca, John
Farrell, Rachel
Feys, Peter
Filippi, Massimo
Freeman, Jennifer
Inglese, Matilde
Meza, Cecilia
Motl, Rob
Rocca, Maria Assunta
Sandroff, Brian M.
Salter, Amber
The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience
title The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience
title_full The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience
title_fullStr The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience
title_full_unstemmed The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience
title_short The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience
title_sort impact of the covid-19 pandemic on an international rehabilitation study in ms: the cogex experience
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570234/
https://www.ncbi.nlm.nih.gov/pubmed/34741240
http://dx.doi.org/10.1007/s00415-021-10881-3
work_keys_str_mv AT feinsteinanthony theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT amatomariapia theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT brichettogiampaolo theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT chatawayjeremy theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT chiaravallotinancyd theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT cuttergary theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT dalgasulrik theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT delucajohn theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT farrellrachel theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT feyspeter theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT filippimassimo theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT freemanjennifer theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT inglesematilde theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT mezacecilia theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT motlrob theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT roccamariaassunta theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT sandroffbrianm theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT salteramber theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT theimpactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT feinsteinanthony impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT amatomariapia impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT brichettogiampaolo impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT chatawayjeremy impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT chiaravallotinancyd impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT cuttergary impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT dalgasulrik impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT delucajohn impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT farrellrachel impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT feyspeter impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT filippimassimo impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT freemanjennifer impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT inglesematilde impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT mezacecilia impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT motlrob impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT roccamariaassunta impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT sandroffbrianm impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT salteramber impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience
AT impactofthecovid19pandemiconaninternationalrehabilitationstudyinmsthecogexexperience